Reported Earlier, Mesoblast Secures BLA Filing Number For Rexlemestrocel-L, Backed By Orphan Drug And RMAT Designations For Priority Review Eligibility

뉴스 본문을 불러오고 있어요.

Reported Earlier, Mesoblast Secures BLA Filing Number For Rexlemestrocel-L, Backed By Orphan Drug And RMAT Designations For Priority Review Eligibility | 웨이프 WAPE

Reported Earlier, Mesoblast Secures BLA Filing Number For Rexlemestrocel-L, Backed By Orphan Drug And RMAT Designations For Priority Review Eligibility

기사 요약

관련 종목

댓글 —